Patents by Inventor Calman Philip Prussin

Calman Philip Prussin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF DEXPRAMIPEXOLE FOR THE TREATMENT OF INADEQUATELY CONTROLLED MODERATE TO SEVERE ASTHMA
    Publication number: 20250205206
    Abstract: A method of treating inadequately controlled severe asthma of the eosinophilic phenotype in a human subject in need thereof is disclosed. The method comprises orally administering to the subject a daily dose of about 150 mg to about 300 mg of dexpramipexole, or a pharmaceutically acceptable salt thereof, wherein the subject is already receiving at least an inhaled corticosteroid (ICS) and a long-acting beta agonist (LABA), thereby treating the inadequately controlled severe asthma. A method of treating inadequately controlled moderate to severe asthma of the eosinophilic phenotype in a human subject in need thereof is also disclosed. The method comprises orally administering to the subject a daily dose of about 150 mg to about 300 mg of dexpramipexole, or a pharmaceutically acceptable salt thereof, wherein the subject is already receiving at least an ICS and an LABA, thereby treating the inadequately controlled moderate to severe asthma.
    Type: Application
    Filed: December 19, 2024
    Publication date: June 26, 2025
    Applicant: Areteia Therapeutics, Inc.
    Inventors: Eric Bradford, Calman Philip PRUSSIN, Gregory C. WILLIAMS, Peter WIJNGAARD, Steven YANCEY
  • USE OF DEXPRAMIPEXOLE FOR THE TREATMENT OF MODERATE TO SEVERE ASTHMA
    Publication number: 20240041840
    Abstract: Disclosed herein are methods of treating moderate to severe asthma of the eosinophilic phenotype in a human subject in need thereof with a daily dose of about 75 mg to about 300 mg of dexpramipexole or pharmaceutical acceptable salt thereof, and treating severe asthma of the eosinophilic phenotype in a human subject in need thereof with a daily dose of about 150 mg to about 300 mg of dexpramipexole or pharmaceutical acceptable salt thereof.
    Type: Application
    Filed: October 11, 2023
    Publication date: February 8, 2024
    Applicant: Areteia Therapeutics, Inc.
    Inventor: Calman Philip PRUSSIN
  • USE OF DEXPRAMIPEXOLE FOR THE TREATMENT OF MODERATE TO SEVERE ASTHMA
    Publication number: 20240041841
    Abstract: Disclosed herein are methods of treating moderate to severe asthma of the eosinophilic phenotype in a human subject in need thereof with a daily dose of about 75 mg to about 300 mg of dexpramipexole or pharmaceutical acceptable salt thereof, and treating severe asthma of the eosinophilic phenotype in a human subject in need thereof with a daily dose of about 150 mg to about 300 mg of dexpramipexole or pharmaceutical acceptable salt thereof.
    Type: Application
    Filed: October 11, 2023
    Publication date: February 8, 2024
    Applicant: Areteia Therapeutics, Inc.
    Inventor: Calman Philip PRUSSIN
  • USE OF DEXPRAMIPEXOLE FOR THE TREATMENT OF MODERATE TO SEVERE ASTHMA
    Publication number: 20220040154
    Abstract: Disclosed herein are methods of treating moderate to severe asthma of the eosinophilic phenotype in a human subject in need thereof with a daily dose of about 75 mg to about 300 mg of dexpramipexole or pharmaceutical acceptable salt thereof, and treating severe asthma of the eosinophilic phenotype in a human subject in need thereof with a daily dose of about 150 mg to about 300 mg of dexpramipexole or pharmaceutical acceptable salt thereof.
    Type: Application
    Filed: August 5, 2021
    Publication date: February 10, 2022
    Inventor: Calman Philip Prussin